1-20 of 21
Michael Kalos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy

Jaafar N. Haidar, Stephen Antonysamy, Sneha Mathew, Lan Wu, Yi Zhang, Margaret C. Kearins, Leyi Shen, J. Michael Sauder, David Schaer, Kyla E. Driscoll, Michael Kalos
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 2753.
https://doi.org/10.1158/1538-7445.AM2019-2753
Published: 01 July 2019
View article titled, Abstract 2753: The molecular basis of blocking the TIM-3 checkpoint with the LY3321367 mAb in cancer immunotherapy
Journal Articles

Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms

David A. Schaer, Nelusha Amaladas, Zhao Hai Lu, Erik Rasmussen, Andreas Sonyi, Darin Chin, Andrew Capen, Yanxia Li, Catalina Meyer, Bonita Jones, Xiaodong Hong, Shuang Luo, Carmine Carpenito, Kenneth Roth, Alexander Nikolayev, Bo Tan, Manisha Brahmachary, Krishna Chodavarapu, Frank Charles Dorsey, Jason Manro, Thompson Doman, Greg Donoho, David Surguladze, Gerald Hall, Sandaruwan Geeganage, Michael Kalos, Ruslan Novosiadly
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3945.
https://doi.org/10.1158/1538-7445.AM2019-3945
Published: 01 July 2019
View article titled, Abstract 3945: The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy via immunogenic tumor cell death and T cell-intrinsic mechanisms
Journal Articles

Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms

Ruslan Novosiadly, David Schaer, Nelusha Amaladas, Erik Rasmussen, Zhao Hai Lu, Andreas Sonyi, Carmine Carpenito, Yanxia Li, Shuang Luo, Andrew Capen, Catalina Meyer, Xiaodong Huang, Jason Manro, Gregory Donoho, Thompson Doman, Gerald Hall, Sandaruwan Geeganage, Michael Kalos
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4549.
https://doi.org/10.1158/1538-7445.AM2018-4549
Published: 01 July 2018
View article titled, Abstract 4549: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms
Journal Articles

Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models

Veena Kandaswamy, Amelie Forest, Marianne Deroose, David A. Schaer, Ting Chen, Shengwu Liu, David Surguladze, Yung-mae Yao, Thompson Doman, Gerald Hall, Kwok-Kin Wong, Michael Kalos, Ruslan D. Novosiadly
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 3632.
https://doi.org/10.1158/1538-7445.AM2018-3632
Published: 01 July 2018
View article titled, Abstract 3632: Combination of EGFR antibody with PD-1 pathway inhibitors improves anti-tumor efficacy and enhances intra-tumor immune response in preclinical mouse tumor models
Journal Articles

Abstract 4569: The CDK4/6 inhibitor abemaciclib synergizes with PD-L1 blockade to induce an immune inflamed tumor microenvironment through T cell and tumor cell intrinsic effects

David Schaer, Richard Beckmann, Jack Dempsey, Lysiane Huber, Amelie Forest, Nelusha Amaladas, Ying Cindy Wang, Erik Rasmussen, Darin Chin, Yanxia Li, Andrew Capen, Marianne Deroose, Carmine Carpenito, Xueqian Gong, Kirk Staschke, Linda Chung, Farhana Merzoug, Trent Stewart, Lacey Litchfield, Philip Iversen, Sean Buchanan, Alfonso de Dios, Ruslan Novosiadly, Michael Kalos
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 4569.
https://doi.org/10.1158/1538-7445.AM2018-4569
Published: 01 July 2018
View article titled, Abstract 4569: The CDK4/6 inhibitor abemaciclib synergizes with PD-L1 blockade to induce an immune inflamed tumor microenvironment through T cell and tumor cell intrinsic effects
Journal Articles

Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor

Huaxing Pei, Saravanan Parthasarathy, Sajan Joseph, William McMillen, Xiaohong Xu, Stephen Castaneda, Ivan Inigo, Karen Britt, Bryan Anderson, Gaiying Zhao, Scott Sawyer, Douglas Beight, Talbi Kaoudi, Chandrasekar Iyer, Huimin Bian, Amy Pappas, David Surguladze, David Schaer, Karim Benhadji, Michael Kalos, Kyla Driscoll
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 955.
https://doi.org/10.1158/1538-7445.AM2017-955
Published: 01 July 2017
View article titled, Abstract 955: LY3200882, a novel, highly selective TGFβRI small molecule inhibitor
Journal Articles

Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model

Sau-Chi Betty Yan, Victoria L. Peek, Jennifer R. Stephens, Um L. Um, Amaladas Nelusha, Colleen A. Burns, Kelly M. Credille, Thompson N. Doman, Scott W. Eastman, Beverly L. Falcon, Gerald E. Hall, Philip W. Iversen, Bruce W. Konicek, Jason R. Manro, Any T. Pappas, Julie A. Stewart, Michael B. Topper, Swee-Seong Wong, Michael Kalos, Ruslan D. Novosiadly, Richard A. Walgren, David Schaer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5590.
https://doi.org/10.1158/1538-7445.AM2017-5590
Published: 01 July 2017
View article titled, Abstract 5590: Combination of an oncokinase inhibitor merestinib with anti-PD-L1 results in enhanced immune mediated antitumor activity in CT26 murine tumor model
Journal Articles

Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade

Jack Dempsey, Lysiane Huber, Amelie Forest, Jennifer R. Stephens, Thompson N. Doman, Jason Manro, Andrew Capen, Robert S. Flack, Gregory P. Donoho, Sean Buchanan, Alfonso De Dios, Kyla Driscoll, Michael Kalos, Ruslan Novosiadly, Richard P. Beckmann, David A. Schaer
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 583.
https://doi.org/10.1158/1538-7445.AM2017-583
Published: 01 July 2017
View article titled, Abstract 583: The CDK4/6 inhibitor abemaciclib induces synergistic immune activation and antitumor efficacy in combination with PD-L1 blockade
Journal Articles

Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming

Aaron Rapoport, Edward Stadtmauer, Luca Melchiori, Ryan Wong, Eduardo Davila, Gwendolyn Binder-Scholl, Tom Holdich, Dan Vogl, Brendan Weiss, Jeffrey Finkelstein, Simon Lacey, Sarah Bond, Marylene Fortin, Yoav Peretz, Joanna Brewer, Alan Bennett, Andrew Gerry, Nick Pumphrey, Helen Tayton-Martin, Lilliam Ribeiro, Ashraf Badros, Saul Yanovich, Nancy Hardy, Jean Yared, Naseem Kerr, Sunita Philip, Sandra Wesphal, Bruce L. Levine, Carl June, Michael Kalos, Bent Jakobsen
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 4701.
https://doi.org/10.1158/1538-7445.AM2015-4701
Published: 01 August 2015
View article titled, Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming
Journal Articles

Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies

Saad Sirop Kenderian, Marco Ruella, Saar Gill, Michael Kalos
Journal: Cancer Research
Cancer Res (2014) 74 (22): 6383–6389.
https://doi.org/10.1158/0008-5472.CAN-14-1530
Published: 13 November 2014
View article titled, Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies
Open the PDF for Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies in another window
Journal Articles

Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL

Stephan A. Grupp, Shannon Maude, Richard Aplenc, David M. Barrett, Michael Kalos, Bruce Levine, Manuel Lichtman, Susan Rheingold, Angela Shen, Christine Strait, David Teachey, Patricia A. Wood, Carl June
Journal: Cancer Research
Cancer Res (2014) 74 (20_Supplement): PR06.
https://doi.org/10.1158/1538-7445.PEDCAN-PR06
Published: 09 October 2014
View article titled, Abstract PR06: T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) produce complete responses and long-term persistence without GVHD in children with relapsed, refractory ALL
Journal Articles

Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma

Namir J. Hassan, Giovanna Bossi, Debbie Baker, Katherine Adams, Jane Harper, Joseph Dukes, Nathaniel Liddy, Samantha Paston, Yvonne McGrath, Tara Mahon, Peter Molloy, Malkit Sami, Emma Baston, Brian Cameron, Andrew Johnson, Annelise Vuidepot, Gerry Linette, Michael Kalos, Carl June, Bent Jakobsen
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2900.
https://doi.org/10.1158/1538-7445.AM2014-2900
Published: 01 October 2014
View article titled, Abstract 2900: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma
Journal Articles

Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses.

Stephan A. Grupp, Michael Kalos, David M. Barrett, David T. Teachey, Bruce Levine, Michael Milone, David Porter, Carl H. June
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4574.
https://doi.org/10.1158/1538-7445.AM2013-4574
Published: 15 April 2013
View article titled, Abstract 4574: Use of CD19-targeted Chimeric Antigen Receptor-modified T (CART19) cells in ALL and CLL produce transient cytokine release syndrome (CRS), macrophage activation syndrome (MAS) and durable responses.
Journal Articles

Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma.

Aaron P. Rapoport, Edward A. Stadtmauer, Dan T. Vogl, Brendan Weiss, Gwendolyn K. Binder-Scholl, Dominic P. Smethurst, Jeffrey Finkelstein, Irina Kulikovskaya, Minnal Gupta, Erica Suppa, Tatiana Mikheeva, Joanna E. Brewer, Alan D. Bennett, Andrew B. Gerry, Nick J. Pumphrey, Helen K. Tayton-Martin, Lilliam Ribeiro, Elizabeth Veloso, Zhaohui Zheng, Ashraf Z. Bados, Saul Yanovich, Gorgun Akpek, Karen Dengel, Naseem Kerr, Sunita Philip, Kelly-Marie Betts, Sandra Westphal, Bruce L. Levine, Bent K. Jakobsen, Carl H. June, Michael Kalos
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4575.
https://doi.org/10.1158/1538-7445.AM2013-4575
Published: 15 April 2013
View article titled, Abstract 4575: Correlates of clinical response following autologous stem cell transplant and adoptive immunotherapy with engineered T cells expressing an affinity-enhanced T cell receptor in patients with mutliple myeloma.
Journal Articles

Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma

Namir J. Hassan, Katherine Adams, Giovanna Bossi, Jane Harper, Sandrine Buisson, Samantha Paston, Nathaniel Liddy, Rebecca Ashfield, Jessie Gavarret, Frayne Bianchi, Emma Baston, Debbie Baker, Kristin Ladell, Andrew Sewell, Yi Li, Brian Cameron, Andrew Johnson, Annelise Vuidepot, Penio Todorov, Michael Kalos, Carl June, Giorgos Karakousis, Gerry Linette, David A. Price, Daniel Williams, Yvonne McGrath, Bent K. Jakobsen
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3525.
https://doi.org/10.1158/1538-7445.AM2012-3525
Published: 15 April 2012
View article titled, Abstract 3525: IMCgp100: A novel bi-specific biologic for the treatment of malignant melanoma
Journal Articles

Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers

Namir J. Hassan, Debbie Baker, Jane Harper, Katherine Adams, Giovanna Bossi, Nathaniel Liddy, Sandrine Buisson, Samantha Paston, Jessie Gavarret, Frayne Bianchi, Emma Baston, Alison Legg, Rebecca Ashfield, Yvonne McGrath, Yi Li, Daniel Williams, Brian Cameron, Andrew Johnson, Annelise Vuidepot, Penio Todorov, Pamela Roberts, Chris Hatton, Michael Kalos, Carl June, Bent K. Jakobsen
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 3528.
https://doi.org/10.1158/1538-7445.AM2012-3528
Published: 15 April 2012
View article titled, Abstract 3528: IMCmage1: A novel bi-specific biologic re-directing T cells to kill MAGE-A3/A6 presenting cancers
Journal Articles

Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing

Samantha J. Paston, Rebecca Ashfield, Nathaniel Liddy, Giovanna Bossi, Katherine Adams, Emmet McCormack, Anna Lissina, Tara Mahon, Namir Hassan, Jessie Gavarret, Frayne Bianchi, Nick Pumphrey, Kristin Ladell, Emma Gostick, Andrew K. Sewell, Nikolai Lissin, Peter Molloy, Yi Li, Brian Cameron, Malkit Sami, Emma Baston, Jane Harper, Andrew Johnson, Annelise Vuidepot, Penio Todorov, Rebecca Dennis, Michael Kalos, Carl June, David A. Price, Daniel Williams, Bent K. Jakobsen
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1787.
https://doi.org/10.1158/1538-7445.AM2011-1787
Published: 15 April 2011
View article titled, Abstract 1787: ImmTACs: Bi-functional reagents for redirected tumour cell killing
Journal Articles

Abstract 4744: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens

Jane V. Harper, Namir J. Hassan, Nathaniel Liddy, Tara Mahon, Giovanna Bossi, Katherine Adams, Jessie Gavarret, Frayne Bianchi, Nikolai Lissin, Peter Molloy, Yi Li, Nick Pumphrey, Brian Cameron, Malkit Sami, Emma Baston, Rebecca Ashfield, Andrew Johnson, Annelise Vuidepot, Yvonne McGrath, Penio Todorov, Samantha Paston, Milos Aleksic, Alison Legg, Debbie Wright, Rebecca Dennis, Andrew K. Sewell, David A. Price, Naomi Harwood, Anna Lissina, Emma Gostik, Carl June, Michael Kalos, Gabriela Pleas, Deborah Sutton, Daniel Williams, Bent Jakobsen
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4744.
https://doi.org/10.1158/1538-7445.AM2011-4744
Published: 15 April 2011
View article titled, Abstract 4744: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens
Journal Articles

Abstract 2933: Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells

David M. Barrett, Carmine Carpenito, Yang Bing Zhao, Michael Kalos, Carl H. June, Stephan A. Grupp
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 2933.
https://doi.org/10.1158/1538-7445.AM10-2933
Published: 15 April 2010
View article titled, Abstract 2933: Pre-clinical model of eradication of B cell leukemia with lentiviral transduced anti-CD19 chimeric immunoreceptor-modified T cells
Journal Articles

Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens

Namir J. Hassan, Nathaniel Liddy, Tara Mahon, Giovanna Bossi, Katherine Adams, Jessie Gavarret, Frayne Bianchi, Nikolai Lissin, Peter Molloy, Yi Li, Nick Pumphrey, Brian Cameron, Malkit Sami, Emma Baston, Jane Harper, Rebecca Ashfield, Andrew Johnson, Annelise Vuidepot, Yvonne McGrath, Penio Todorov, Samantha Paston, Rebecca Dennis, Andrew K. Sewell, David A. Price, Naomi Harwood, Anna Lissina, Emma Gostick, Carl June, Michael Kalos, Gabriela Plesa, Deborah Sutton, Daniel Williams, Bent K. Jakobsen
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5616.
https://doi.org/10.1158/1538-7445.AM10-5616
Published: 15 April 2010
View article titled, Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens